These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 7898536)

  • 1. The treatment of candidemia.
    DiNubile MJ
    N Engl J Med; 1995 Apr; 332(16):1100-1; author reply 1101-2. PubMed ID: 7898536
    [No Abstract]   [Full Text] [Related]  

  • 2. The treatment of candidemia.
    Girmenia C; Martino P
    N Engl J Med; 1995 Apr; 332(16):1101; author reply 1101-2. PubMed ID: 7898538
    [No Abstract]   [Full Text] [Related]  

  • 3. The treatment of candidemia.
    Cofsky RD
    N Engl J Med; 1995 Apr; 332(16):1101; author reply 1101-2. PubMed ID: 7898537
    [No Abstract]   [Full Text] [Related]  

  • 4. [Current treatment of candidemia in non-neutropenic patients. Amphotericin B or fluconazole? A retrospective study of 62 consecutive patients].
    Cobo Reinoso P; Aguado García JM; Lumbreras Bermejo C; Pérez Vela JL; Caballero Cubedo R; Sanz Sanz F; Noriega Rodríguez AR
    Rev Clin Esp; 1997 Dec; 197(12):799-803. PubMed ID: 9477669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The treatment of candidemia.
    Tang CM; Howe P; Crook DW
    N Engl J Med; 1995 Apr; 332(16):1101; author reply 1101-2. PubMed ID: 7898539
    [No Abstract]   [Full Text] [Related]  

  • 6. The fluconazole era: management of hematogenously disseminated candidiasis in the nonneutropenic patient.
    Kramer KM; Skaar DJ; Ackerman BH
    Pharmacotherapy; 1997; 17(3):538-48. PubMed ID: 9165556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of candidemia.
    Meunier F
    N Engl J Med; 1994 Nov; 331(20):1371-2. PubMed ID: 7935710
    [No Abstract]   [Full Text] [Related]  

  • 8. Fluconazole plus amphotericin B combinations are not contraindicated and may add benefit for the treatment of candidemia.
    Odds FC
    Clin Infect Dis; 2003 May; 36(10):1229-31. PubMed ID: 12746766
    [No Abstract]   [Full Text] [Related]  

  • 9. Systemic and gastrointestinal candidiasis of infant mice as model for antifungal therapy.
    Ponnuvel KM; Rama CP; Menon T
    Indian J Exp Biol; 1993 May; 31(5):450-2. PubMed ID: 8359853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.
    Rex JH; Pappas PG; Karchmer AW; Sobel J; Edwards JE; Hadley S; Brass C; Vazquez JA; Chapman SW; Horowitz HW; Zervos M; McKinsey D; Lee J; Babinchak T; Bradsher RW; Cleary JD; Cohen DM; Danziger L; Goldman M; Goodman J; Hilton E; Hyslop NE; Kett DH; Lutz J; Rubin RH; Scheld WM; Schuster M; Simmons B; Stein DK; Washburn RG; Mautner L; Chu TC; Panzer H; Rosenstein RB; Booth J;
    Clin Infect Dis; 2003 May; 36(10):1221-8. PubMed ID: 12746765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Candida glabrata fungemia cured by antibiotic-lock therapy: case report and short review.
    Angel-Moreno A; Boronat M; Bolaños M; Carrillo A; González S; Pérez Arellano JL
    J Infect; 2005 Oct; 51(3):e85-7. PubMed ID: 16230210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Candidemia: a never ceasing challenge].
    Muñoz García de Paredes P
    Rev Clin Esp; 1997 Dec; 197(12):795-7. PubMed ID: 9477668
    [No Abstract]   [Full Text] [Related]  

  • 13. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy.
    Hachem R; Hanna H; Kontoyiannis D; Jiang Y; Raad I
    Cancer; 2008 Jun; 112(11):2493-9. PubMed ID: 18412153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for breakthrough candidemia.
    Nucci M; Colombo AL
    Eur J Clin Microbiol Infect Dis; 2002 Mar; 21(3):209-11. PubMed ID: 11957023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiology and treatment of hematogenous candidiasis: a Brazilian perspective.
    Colombo AL
    Braz J Infect Dis; 2000 Jun; 4(3):113-8. PubMed ID: 10934493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current strategies for treating invasive candidiasis: emphasis on infections in nonneutropenic patients.
    Edwards JE; Filler SG
    Clin Infect Dis; 1992 Mar; 14 Suppl 1():S106-13. PubMed ID: 1562680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pfizer's Vfend as effective in treating candidemia as two-drug standard of care according to study.
    Infection; 2004 Jun; 32(3):8. PubMed ID: 15230277
    [No Abstract]   [Full Text] [Related]  

  • 18. [Epidemiology of fungemia in a university hospital; therapeutic incidence].
    Pavese P; Brion JP; Lebeau B; Grillot R; Ambroise-Thomas P
    Pathol Biol (Paris); 1999 May; 47(5):579-83. PubMed ID: 10418046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Community-acquired fungemia due to a multiple-azole-resistant strain of Candida tropicalis.
    Jandourek A; Brown P; Vazquez JA
    Clin Infect Dis; 1999 Dec; 29(6):1583-4. PubMed ID: 10585825
    [No Abstract]   [Full Text] [Related]  

  • 20. Candida lusitaniae: a cause of breakthrough fungemia in cancer patients.
    Minari A; Hachem R; Raad I
    Clin Infect Dis; 2001 Jan; 32(2):186-90. PubMed ID: 11170906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.